TheChek News Flow

RTRS - QATAR AIRWAYS CEO SAYS AIRLINE HAS "SUFFICIENT A380S FOR THE TIME BEING" AIR.PA BA.N

RIG US - Hearing vague chatter of activist involvement pushing for possible sale

Hearing strength attributed to Charter/Time Warner Cable deal - Chatter points to Voltari being a big Time Warner Cable supplier

Seeing early put activity - Aug 60 puts traded 1600 times

CNBC's Faber citing sources: Altice will not be coming back to make a formal bid for TWC, Altice was thinking to offer $150-160 in cash and $50/shr in stock

Gapping down
In reaction to disappointing earnings/guidance: CYRN -7.9%, MOBI -6.1%, TTM -4.8%, TOUR -3.6%, WUBA -2.7%, MAGS -0.6%, PLAY -0.4%

Select EU financial related names showing weakness: SAN -2.8%, DB -2%, NBG -1.5%, CS -1.5%, BCS -1.3%

Select metals/mining stocks trading lower with underlying commodity down ~1%: GFI -4.6%, HMY -4.5%, AU -3%, HL -2.2%, GOLD -2.1%, SLV -2%, GG -1.8%, AEM -1.8%, GDX -1.8%, KGC -1.7%, EGO -1.4%, SLW -1.4%, AG -1.1%

Select oil/gas related names showing early weakness with underlying commodity down ~1%: SDRL -3.2%, PBR -2.7%, RIG -2%, RDS.A -1.7%, STO -1.7%, TOT -1.4%

Other news: IMRS -17.7% (IMRIS and two subsidiaries confirm filing for Chapter 11 bankruptcy protection), ACI -9.4% (receives continued listing standard notice from NYSE; taking steps to regain compliance with minimum share price standard), INO -3.7% (files for $250 mln mixed securities shelf offering), POZN -3.1% (confirms that on May 21, 2015, The Coalition for Affordable Drugs VII LLC filed a Petition for Inter Partes Review of POZEN Inc.'s U.S. Patent No. 6,926,907), SHAK -2.7% (modest pullback following strong gains last week), PBR -2.7% (still checking), AZN -1.7% (confirmed the termination of its co-development and commercialisation agreement with Amgen (AMGN) for brodalumab), AMGN -1.1% (commenced termination of its participation in the co-development and commercialization of brodalumab with AstraZeneca (AZN))

Analyst comments: ANR -5.2% (initiated with a Underperform at Credit Suisse), FSLR -3.8% (downgraded to Underperform from Sector Perform at RBC Capital Mkts), NBR -2% (downgraded to Underperform from Outperform at Credit Agricole), HW -1.3% (downgraded to Neutral from Outperform at Wedbush), DE -0.7% (downgrade to Neutral at Robert W. Baird ), HBAN -0.7% (downgraded to Underperform from Neutral at Macquarie
)

Gapping up
In reaction to strong earnings/guidance: RYAAY +4.3%, AZO +1.3%, SKYS +0.4%

M&A news: GKNT +118.6% (to be acquired by Hot Topic for $17.50 per share), LPSN +11.4% (Nice Systems (NICE) takeover speculation), TWC +7.5% (Time Warner Cable confirms it has signed a deal to be acquired by Charter Comm (CHTR) for $195.71/share), CHTR +3.7% (Time Warner Cable confirms it has signed a deal to be acquired by Charter Comm (CHTR) for $195.71/share), EMC +0.9% (to acquire Virtustream, for $1.2 bln in cash)

Other news: IPCI +21% (confirms FDA grants fast track designation for Intellipharmaceutics Rexista Oxycodone XR Incorporating PODRAS Technology), PBMD +10.2% (was up 8%, now lower after releasing press release that is essentially the same press release that was released on 5/19), AEZS +9.3% (announces receipt of advice from the EMA, for the study design of its Phase 3 Study of Macrilen), CERU +9.2% (confirms it has been granted orphan drug designation for CRLX101 for the treatment of ovarian cancer by the FDA), MDR +9.2% (positive Barron's mention/Saudi Aramco contract), CVC +6.1% (following CHTR/TWC deal), ISR +6% (cont volatility), FXCM +4.9% (news Friday afternoon that U.S. & U.K subsidiaries agreed to assume the vast majority of margin forex accounts of CitiFX Pro from Citibank N.A), FOLD +4.9% (confirms that the EMA CHMP has granted Accelerated Assessment for the co's Migalastat HCl monotherapy for Fabry patients), ONTY +3.3% (cont strength), AEGR +3.1% (announces it has achieved the primary endpoint in its Phase III Study of Lomitapide, to treat Homozygous Familial Hypercholesterolemia), PBY +1.8% (Glenhill Advisors discloses 7.0% active stake in 13D filing; to engage in dialogue with co), FEYE +1.6% (favorable commentary on Friday's Mad Money), BLDP +1.4% (receives order for breakthrough technology solutions project with Nisshinbo), JASO +1% (JA Solar and Essel Infraprojects sign MOU to establish a solar cell and module manufacturing facility with 500MW production capacity)

Analyst comments: CTRP +4.3% (target raised to $122 from $80 at Summit Research), BPMC +3.5% (initiated with an Outperform at Cowen), PRTY +1.9% (initiated with a Overweight at Morgan Stanley, initiated with a Overweight at JP Morgan, among others), MRVL +1.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley), LB +1.9% (added to Conviction Buy List at Goldman), BLUE +1.5% (target raised to $213 from $186 at Piper Jaffray), BSM +1.2% (initiated with an Overweight at Barclays), CEO +1.1% (upgraded to Neutral from Underweight at JP Morgan), PANW +1% (target raised to $175 at RBC Capital Mkts), EVA +0.9% (initiated with a Buy at Goldman, among others
)